Skip to main content

Market Overview

Juno Therapeutics Soars 25% After ROCKET Phase 2 Rocket Trial Resumption

Share:
Juno Therapeutics Soars 25% After ROCKET Phase 2 Rocket Trial Resumption

Shares of Juno Therapeutics Inc (NASDAQ: JUNO) soared higher by nearly 25 percent to $34.50 ahead of Wednesday's market open. The biopharma company focused on the treatment of cancer announced after Tuesday's market close that the U.S. Food and Drug Administration removed a clinical hold on the Phase II clinical trial of JCAR015, also known as the "ROCKET" trial.

The clinical hold was placed last week after two patients that participated in the clinical trial died.

Related Link: Juno Therapeutics Plunges 30% After 2 Patient Deaths From Lead Cancer Drug

Juno confirmed in its press release on Tuesday that the "ROCKET" trial will continue under a revised protocol.

Biotechs Move Higher

Shares of Kite Pharma Inc (NASDAQ: KITE), a developer of cancer immunotherapy products to eradicate cancer cells, were trading higher by more than 7 percent early Wednesday morning.

Shares of Cellectis SA (ADR) (NASDAQ: CLLS), a specialist in the research and development of rational genome engineering technologies, were trading higher by more than 6 percent.

Meanwhile, the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB) was trading higher by just 0.20 percent at $273.11.

 

Related Articles (JUNO)

View Comments and Join the Discussion!

Posted-In: Biopharmaceutical CompaniesBiotech Long Ideas News FDA Movers Trading Ideas General Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com